Physician profile
Constantine Bakas
NPI 1194895177
$1,138.74
in general payments reported to CMS, 2019-2025
16 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $59.48 · 2022: $170 · 2023: $147 · 2024: $228 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $168.72 | 2025 | Zurzuvae |
| Abbvie INC. | $158.53 | 2019-2020 | |
| Amgen INC. | $127.72 | 2024 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $120.08 | 2019-2022 | |
| Meditrina | $90.02 | 2023 | |
| Exeltis, USA INC. | $83.94 | 2019-2024 | Slynd |
| Shield Therapeutics INC | $69.33 | 2023-2024 | Accrufer |
| Myovant Sciences INC. | $65.37 | 2022 | |
| Merck Sharp & Dohme LLC | $62.23 | 2019-2020 | |
| Coopersurgical, INC. | $43.04 | 2022 | |
| Astellas Pharma US INC | $42.47 | 2019-2024 | Veozah |
| Daiichi Sankyo INC. | $29.85 | 2019 | |
| Evofem Biosciences, INC. | $25.93 | 2022 | |
| Organon LLC | $19.22 | 2023 | Nexplanon |
| Therapeuticsmd, INC. | $16.25 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Bakas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.